Integrated Biopharma Inc (INBP): Revenue
$43.87M
Year ended 2026-06-30
-4.7%
3-year compound annual growth
-7.1%
5-year compound annual growth
+0.4%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $43.87M | -19.3% | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | $54.35M | +8.0% | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | $50.32M | -0.7% | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $50.67M | -9.9% | 2024-09-20, From 2022-07-01 |
| 2022-06-30 | $56.25M | -11.5% | 2023-09-15, From 2021-07-01 |
| 2021-06-30 | $63.56M | +20.4% | 2022-09-13, From 2020-07-01 |
| 2020-06-30 | $52.77M | +5.6% | 2021-09-02, From 2019-07-01 |
| 2019-06-30 | $49.98M | +14.3% | 2020-09-23, From 2018-07-01 |
| 2018-06-30 | $43.71M | -6.9% | 2019-08-29, From 2017-07-01 |
| 2017-06-30 | $46.95M | +11.2% | 2018-09-12, From 2016-07-01 |
| 2016-06-30 | $42.21M | +12.6% | 2017-09-01, From 2015-07-01 |
| 2015-06-30 | $37.49M | +11.3% | 2016-09-02, From 2014-07-01 |
| 2014-06-30 | $33.68M | +0.2% | 2015-09-04, From 2013-07-01 |
| 2013-06-30 | $33.62M | -8.1% | 2013-09-30, From 2012-07-01 |
| 2012-06-30 | $36.60M | n/a | 2013-09-30, From 2011-07-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $43.87M | -19.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $43.77M | +589.9% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $44.52M | +17.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $44.55M | -22.6% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $42.73M | -60.5% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $45.95M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $46.02M | -89.4% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $41.70M | +11.7% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $48.47M | -57.7% |
Compare INBP, XLO, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗